EFFICACY OF RANOLAZINE IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD)

Trial Profile

EFFICACY OF RANOLAZINE IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD)

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Sponsors Menarini
  • Most Recent Events

    • 02 Apr 2016 Status changed from recruiting to discontinued, according to European Clinical Trials Database record.
    • 23 Oct 2013 Status changed from active, no longer recruiting to recruiting as reported by United Kingdom Clinical Research Network record.
    • 09 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top